Applied StemCell provides industry and academic researchers with the ability to leverage the power of induced pluripotent stem cells (iPSC) technology.
Headquartered in Milpitas, California. Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California.
02/24/2026
What if you could skip clonal purification—and still get consistent expression?
TARGATT™ large knock-in technology enables safe, site-specific integration into a validated safe harbor, delivering uniform expression across cells without the time and uncertainty of traditional workflows.
With demonstrated payloads up to 50 kb, the TARGATT™ platform supports complex, multi-cassette designs for next-generation therapeutic development.
Faster cell line development. Less variability. More predictable outcomes.
Today, on the International Day of Women and Girls in Science, we're celebrating the women at Applied StemCell who dedicate their talent, curiosity, and expertise to advancing life-saving biology every day.
From research and development to operations and beyond, women across our company play a vital role in driving innovation and delivering high-quality iPSC and genome engineering solutions that support the development of next-generation cell therapies.
At Applied StemCell, we’re committed to fostering a workplace where women are supported, valued, and empowered to grow at every stage of their careers—whether they’re at the bench, in the boardroom, or working across disciplines to move cell line engineering forward.
As Eimi Oda, a Research Associate on our Cell Engineering team, puts it:
“Confidence comes from learning, asking questions, and allowing yourself to grow.”
We encourage our peers to join us in inspiring the next generation of women and girls in science. Let’s build a future where innovation reflects the diversity of the world it serves.
Science is for everyone.
02/04/2026
World Cancer Day is a moment to recognize the profound impact of cancer and the global efforts underway to better understand it, prevent it, and improve outcomes for patients worldwide.
One study we’re especially excited about demonstrates how genome engineering can uncover the mechanisms that drive cancer progression. In their work, Ranade et al. (https://go.nature.com/46uW02t) used CRISPR-based genome engineering to study metastatic behavior in colorectal cancer (CRC).
By knocking out the MIEN1 promoter region in an HT29 CRC cell line, the researchers observed significant changes to the cells’ actin cytoskeleton—a structure that plays a critical role in how cancer cells move and spread. These findings point to MIEN1 as a promising therapeutic target for limiting metastasis.
We’re proud to have supported this work as the genome engineering partner behind the MIEN1 knock-out, helping enable research that brings us closer to more effective cancer treatments. It’s research like this that motivates us to invest in advanced genome engineering solutions that help answer complex biological questions.
At Applied StemCell, we excel at complex genome engineering services, ranging from multiple knock-outs and point mutations to large cargo insertions enabled by our TARGATT™ technology.
Learn more about our cell line engineering services and let’s work together toward a healthier future: https://bit.ly/3ZizWnX
01/22/2026
What would you cure with a 50 kb knock-in?
With the demonstrated ability to knock in at least 50 kb of DNA into a safe harbor site in the human genome and achieve robust, consistent expression, TARGATT™ technology opens the door to new cell therapy approaches:
• Integrate large genes
• Express multi-gene constructs
• Engineer sophisticated structures such as logic-gated CARs
• Insert multiple expression cassettes
See the data showing how TARGATT™ technology inserted a 50 kb donor plasmid—synthesized in under one month by Ansa Biotechnologies, Inc.—into human iPSCs, leading to robust constitutive and induced protein expression.
Need precise, single-copy DNA integration in mammalian cells? TARGATT™ large knock-in technology makes it possible.
Unlike lentivirus or transposons, which integrate randomly and in multiple copies, the TARGATT™ platform inserts site-specifically and in single copy at its designated landing pad.
This precision enables applications in mammalian cells that were previously challenging, including library creation, pool-based screening, and more.
And because the TARGATT™ integrase destroys att sites during recombination, the reaction is unidirectional, preventing excision and maximizing efficiency.
See the single-copy insertion data in the image below:
FIGURE CAPTION: We co-transfected GFP and mCherry TARGATT™ donor plasmids into CHO cells (A) and imaged the resulting cells using the green channel (B), the red channel (C), and as an overlay (D). In the overlay, the lack of yellow cells—cells that express both GFP and mCherry—demonstrate that genomic insertion using TARGATT™ technology only occurs in single copy.
12/19/2025
What would you cure with a 50 kb knock-in?
With the demonstrated ability to knock in at least 50 kb of DNA into a safe harbor site in the human genome and achieve robust, consistent expression, TARGATT™ technology opens the door to new cell therapy approaches:
• Integrate large genes
• Express multi-gene constructs
• Engineer sophisticated structures such as logic-gated CARs
• Insert multiple expression cassettes
See the data showing how TARGATT™ technology inserted a 50 kb donor plasmid—synthesized in under one month by Ansa Biotechnologies—into human iPSCs, leading to robust constitutive and induced protein expression.
Meet with James at Poster 48 at Antibody Engineering and Therapeutics US and learn about different approaches for engineering mammalian cells to express difficult proteins with TARGATT™ technology.
Engineering transgenic mammalian cell lines for protein production can be time-consuming and labor-intensive—especially when trying to achieve inducible expression—which is why we used TARGATT™ technology.
Find out more about our three different strategies at Poster 48, viewable any time after 12:00pm on Monday, December 15. We encourage you to join us during the designated poster viewing session beginning at 6:15pm that same day.
If you aren’t able to make it to our poster session, we’ll be at Booth 608. We look forward to speaking with you in San Diego!
12/09/2025
Join Kaytrina and Simon in Boston!
Our ASC team will be at ISSCR’s PSC-Derived Therapies Symposium from December 11 to December 12. Harness this great opportunity to meet with our team and learn about how you can fuel your discovery with the power of iPSCs.
Our iPSC reprogramming, gene editing, and differentiation services combined with our deep scientific expertise, proprietary processes, and regulatory insight are designed to support your success.
We’re here as your partner in all your iPSC endeavors.
Join us at Antibody Engineering & Therapeutics 2025 in San Deigo to explore how TARGATT™ large knock-in technology can accelerate your antibody discovery and development.
Our genome engineering platform enables the construction of large libraries directly in mammalian cells, delivering consistent protein expression for pool-based screening. Achieve more relevant data, greater confidence, and faster results—without relying on bacterial or yeast display systems.
Let’s connect. Visit us at Booth 608 or schedule a meeting with our team through the partnering app.
Safe travels, we’ll see you in San Diego!
12/02/2025
Simplify large DNA insertions into mammalian cells.
With pre-engineered cells equipped with our TARGATT™ large knock-in technology, our kits streamline site-specific, multiprotein insertions into the mammalian H11 safe harbor site so you can achieve efficient and reliable expression.
Our TARGATT™ kits:
• Accelerate allogeneic cell therapy development with the ability to knock-in immune evasion components, therapeutic payloads, and logic gates all in a single reaction
• Speed cell line engineering for expression of difficult proteins and multi-protein constructs
• Enable tight stoichiometric control of multi-protein constructs
• And more!
What will it take to bring iPSC-based therapies to the bedside?
Allogeneic approaches are the most promising way for the drug discovery industry to build scalable and cost-effective cell therapies, but donor cell rejection remains an ongoing challenge.
Join Simon Wu, Ph.D., at ISSCR’s PSC-Derived Therapies Symposium to learn more about Applied StemCell’s approaches to building a hypoimmunogenic cell line and how TARGATT™ technology streamlines safer development.
Eliminating the need for lengthy clonal purification workflows, TARGATT™ large knock-in technology delivers consistent expression from cell to cell—accelerating mammalian cell line development and reducing downstream variability.
The key is safe, efficient insertion into the TARGATT™ safe harbor site.
Demonstrated for payloads up to 50 kb, TARGATT™ technology enables multi-cassette gene expression for advanced therapeutic development and more.
Be the first to know and let us send you an email when Applied StemCell, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California. Our goal is to advance gene-editing and stem cell innovationfor biomedical research and the biotechnology industry. After years of research and development, ASC is proud to offer an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications.
We are currently focusing on three areas:
Cell line generation for bio-production and bioassays
Patient-relevant cell models for personalized medicine and
Physiologically predictive animal models of human diseases
We are striving to improve and expand our technologies and product lines to meet the increasing requirements of the biomedical community.
Establishing disease-specific isogenic models
Developing master cell lines for antibody/protein production
Generating iPSCs from patients containing the corrected mutations or inserted genes for pre-clinical applications
Generating animal models (mouse/rat models)
Using our TARGATT™ technology, a gene-of-interest can be specifically inserted at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression.
This site-specific Knock-in technology has been first established in mouse models, and we have successfully applied it to human cell lines.
We are moving forward to various projects that will combine the CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression.
